摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2-(4-fluorophenyl)-4-methylthiazol-5-yl)methanol | 317319-23-6

中文名称
——
中文别名
——
英文名称
(2-(4-fluorophenyl)-4-methylthiazol-5-yl)methanol
英文别名
[2-(4-Fluorophenyl)-4-methyl-1,3-thiazol-5-yl]methanol
(2-(4-fluorophenyl)-4-methylthiazol-5-yl)methanol化学式
CAS
317319-23-6
化学式
C11H10FNOS
mdl
——
分子量
223.271
InChiKey
JENCFLAMJRGILT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    61.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2-(4-fluorophenyl)-4-methylthiazol-5-yl)methanol二氯甲烷甲苯 为溶剂, 生成 (2-((2-(4-fluorophenyl)-4-methylthiazol-5-yl)methoxy)-2-oxoethyl)triphenylphosphonium bromide
    参考文献:
    名称:
    作为癌细胞线粒体靶向抑制剂的新型噻唑衍生物的设计、合成和生物学评价
    摘要:
    线粒体是细胞维持必要代谢活动的关键能量生产来源。针对功能失调的线粒体特征一直是线粒体相关疾病研究的热点。对癌性线粒体代谢的研究是肿瘤治疗中持续关注的问题。在此,我们基于我们早期对线粒体靶向剂的研究,着手评估新型 TPP-噻唑衍生物家族的抗癌活性。具体而言,我们设计并合成了一系列 TPP-噻唑衍生物,并通过 MTT 测定显示大多数合成的化合物有效抑制了三种癌细胞系(HeLa、PC3 和 MCF-7)。在结构修改后,我们探索了 SAR 关系并确定了最有希望的化合物R13(IC50 of 5.52 μM) 用于进一步研究。同时,我们进行了 ATP 产生测定以评估所选化合物对 HeLa 细胞能量产生的抑制作用。结果显示测试化合物显着抑制癌细胞的ATP产生。总体而言,我们设计并合成了一系列对癌细胞具有显着细胞毒性并有效抑制线粒体能量产生的化合物。
    DOI:
    10.1016/j.bioorg.2021.105015
  • 作为产物:
    描述:
    ethyl 2-(4-fluorophenyl)-4-methylthiazole-5-carboxylate 在 sodium tetrahydroborate 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 0.5h, 生成 (2-(4-fluorophenyl)-4-methylthiazol-5-yl)methanol
    参考文献:
    名称:
    新型噻唑类游离脂肪酸受体1激动剂用于2型糖尿病的设计,合成及构效关系研究
    摘要:
    游离脂肪酸受体1(FFA1 / GPR40)作为治疗2型糖尿病的新靶标已引起人们的关注。相对较高的分子量和亲脂性阻碍了包括FAK1激动剂在内的数个系列的FFA1激动剂(由于对肝毒性的担忧而在III期研究中终止的最先进的化合物)。为了通过降低亲脂性来开发具有低肝毒性风险的有效FFA1激动剂,TAK-875的中间苯基被11个极性五元杂芳族化合物所取代。随后,对SAR的系统探索和分子建模的应用导致了化合物44的鉴定,它是一种出色的FFA1激动剂,在正常和2型糖尿病小鼠中均具有强大的降血糖作用,即使在两倍摩尔的TAK-875剂量下也具有低血糖风险和肝毒性。同时,指出了两个重要发现。首先,我们的噻唑系列中的甲基占据了一个小的疏水亚口袋,与TAK-875没有相互作用。此外,激动活性显示与噻唑核心和末端苯环之间的二面角具有良好的相关性。这些结果促进了对配体结合口袋的了解,并可能有助于设计更有希望的FFA1激动剂。
    DOI:
    10.1016/j.ejmech.2016.02.040
点击查看最新优质反应信息

文献信息

  • Synthesis, antitubercular and antimicrobial potential of some new thiazole substituted thiosemicarbazide derivatives
    作者:Yogita K. Abhale、Abhijit Shinde、Keshav K. Deshmukh、Laxman Nawale、Dhiman Sarkar、Pravin C. Mhaske
    DOI:10.1007/s00044-017-1955-1
    日期:2017.10
    resistance due to multiple factors has warranted the need for search of new compounds which are active against multidrug resistant pathogens. In this context a small focused library of thiosemicarbazide derivatives of 2-arylthiazole-4-carbaldehyde, 4-methyl-2-arylthiazole-5-carbaldehyde and 1-(4-methyl-2-arylthiazol-5-yl) ethanone, (5a–l) has been synthesized. The title compounds were screened for inhibitory
    由于多种因素引起的抗生素耐药性的增加,保证了需要寻找对多药耐药病原体具有活性的新化合物。在这种情况下,一个小型的图书馆集中了2-芳基噻唑-4-甲醛,4-甲基-2-芳基噻唑-5-甲醛和1-(4-甲基-2-芳基噻唑-5-基)乙酮的硫代氨基脲衍生物(5a – l)已合成。筛选标题化合物对结核分枝杆菌H37Ra(ATCC 25177)和牛分枝杆菌Bacille Calmette Guerin菌株(ATCC 35743)的抑制活性。合成的化合物5a – l进一步测定了它们对两种人癌细胞系HeLa和人结肠癌116细胞系的细胞毒活性,并且在所评估的最大浓度下对这两种细胞系没有明显的细胞毒活性。此外,发现合成的化合物对革兰氏阴性菌,大肠杆菌,假单胞菌荧光和革兰氏阳性菌,金黄色葡萄球菌,枯草芽孢杆菌具有潜在的抗菌活性。大多数合成化合物对真菌菌株白色念珠菌具有中等活性。这项研究为我们正在进行的合理设计更有效的抗分枝杆菌药物的努力提供了宝贵的指导。
  • Synthesis, antimycobacterial screening and molecular docking studies of 4-aryl-4′-methyl-2′-aryl-2,5′-bisthiazole derivatives
    作者:Yogita K. Abhale、Abhijit D. Shinde、Keshav K. Deshmukh、Laxman Nawale、Dhiman Sarkar、Prafulla B. Choudhari、Santosh S. Kumbhar、Pravin C. Mhaske
    DOI:10.1007/s00044-017-1988-5
    日期:2017.11
    A series of 4-aryl-4'-methyl-2'-aryl-2,5'-bisthiazole derivatives (5a-o) were synthesized and screened for inhibitory activity against Mycobacterium tuberculosis H37Ra (ATCC 25177) and Mycobacterium bovis BCG (ATCC 35743) strains. Five lead compounds (5e, 5f, 5g, 5h, and 5o) were further confirmed from their dose dependent effect against MTB and Bovine-Calmette-Guerin. The most promising compounds 5f (MIC90: 11.32 mu g/mL), 5h (MIC90: 11.59 mu g/mL), and 5o (MIC90: 23.64 mu g/mL) showed strong antitubercular activity against dormant MTB and BCG as well as almost insignificant cytotoxicity up to 100 mu g/mL against HeLa, A549, and PANC-1 human cancer cell lines. Further, the synthesized compounds were found to have potential antibacterial activity against Gram-negative bacteria, Escherichia coli, Pseudomonas flurescence and Gram-positive bacteria, Staphylococcus aureus, Bacillus subtilis. Most of the synthesized compounds showed moderate activity against fungal strain Candida albicans. Molecular docking studies of these compounds showed significant interactions with crystal structure of the cytochrome P45014 alpha-sterol demethylase (CYP51) PDB ID: 1E9X. Hydrogen bond interactions with SER261 and VAL395 are important interactions for selective inhibition of designed inhibitors. Compounds 5f, 5h, and 5o showed significant interactions with 1E9X. All the experimental results promote us to consider this series as a starting point for the development of novel, selective and more potent antitubercular agents in the future.
  • Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents
    作者:Wenbo Zhou、Anling Huang、Yong Zhang、Qingxiang Lin、Weikai Guo、Zihua You、Zhengfang Yi、Mingyao Liu、Yihua Chen
    DOI:10.1016/j.ejmech.2015.04.027
    日期:2015.5
    Therapeutics of metastatic or triple-negative breast cancer are still challenging in clinical. Herein we demonstrated the design and optimization of a series of hybrid of 2,4-diaminopyrimidine and arylthiazole derivatives for their anti-proliferative properties against two breast cancer cell lines (MCF-7 as human breast cancer and MDA-MB-231 as triple-negative breast cancer). More importantly, some of those compounds with potent antiproliferative activities also indicated excellent inhibitory activities against MDA-MB-231 cell migration. These results suggested that the new series of hybridation of arylthiazoles and aminopyrimidines could be identified and developed as novel highly potential anticancer agents against the triple-negative breast cancer as well as metastatic one in the future. (C) 2015 Elsevier Masson SAS. All rights reserved.
  • Synthesis and antimycobacterial evaluation of new 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-methyl-2-arylthiazole derivatives
    作者:Vikas Shinde、Pramod Mahulikar、Pravin C. Mhaske、Shakti Chakraborty、Amit Choudhari、Siddharth Phalle、Prafulla Choudhari、Dhiman Sarkar
    DOI:10.1007/s00044-019-02310-y
    日期:2019.6
    A new series of 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-methyl-2-arylthiazole derivatives, 6a-w have been synthesized by click reaction of substituted benzylazide, 5a-d with 5-ethynyl-4-methyl-2-substituted phenylthiazole, 4a-f. The starting compounds 4-ethynyl-2-substituted phenylthiazole (4a-f) were synthesized from the corresponding thiazole aldehyde by using the Ohira-Bestmann reagent. The structure of the synthesized compounds was determined by spectral analysis. All the synthesized compounds were screened for their preliminary antitubercular activity against Mycobacterium tuberculosis H37Ra (MTB, ATCC 25177). Most of the synthesized compounds reported good activity against M. tuberculosis H37Ra strain with IC50 range of 0.58-8.23 mu g/mL. Compounds 6g and 6k reported good antitubercular activity with MIC90 values of 4.71 and 2.22 mu g/mL, respectively. Potential antimycobacterial activity suggested that these compounds could serve as good lead compounds for further optimization and development of a newer antitubercular candidate.[GRAPHICS].
  • Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid
    作者:Cheng Chen、Shi-Meng Guo、Yuanjun Sun、He Li、Nan Hu、Kun Yao、Huxin Ni、Zhikan Xia、Bin Xu、Xin Xie、Ya-Qiu Long
    DOI:10.1016/j.ejmech.2023.115267
    日期:2023.5
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺